Galapagos is a midsized biotechnology company, with therapeutic programs based on proprietary disease modifying drug targets, and a focus on inflammation, orphan disease, and anti infectives. Galapagos approach is to develop drugs that stop or reverse a disease state using novel targets that are identified through a patent protected target discovery platform. Galapagos also provides access to its target and drug discovery platform through its services division, BioFocus and Argenta, which offers a full suite of target to drug discovery products and services to pharmaceutical and biotech companies.
Quote | Galapagos NV (NASDAQ:GLPG)
|Last Trade Date Time:||12/01/2023 03:00:00 am|
News | Galapagos NV (NASDAQ:GLPG)
2023-11-21 11:00:00 ET Summary Galapagos pivots to CAR-T therapy, divesting Jyseleca; faces clinical, market risks amidst investor skepticism. Revenue up 9% YOY; operating losses reduced; strong cash reserve at $4.2B; net profit achieved. Negative enterprise value and underper...
2023-11-05 09:14:09 ET Galapagos NV (GLPG) Q3 2023 Earnings Conference Call November 3, 2023 08:00 AM ET Company Participants Sofie Van Gijsel - Head, IR Paul Stoffels - CEO, Chairman, Interim Head, R&D Thad Huston - CFO & COO Jeevan Shetty - Head of ...
Message Board Posts | Galapagos NV (NASDAQ:GLPG)
|Galapagos announces full year 2022 results and outlook||abrooklyn||investorshub||03/31/2023 3:48:40 PM|
|whytestocks: $GLPG News Article - Correction: Jyseleca (filgotinib) approved in Japan for rheumatoid||whytestocks||investorshangout||09/25/2020 5:50:47 PM|
|$GLPG and $GILD both are hot!||BottomBounce||investorshub||06/08/2020 5:45:46 PM|
|I think an upcoming merger is far more important... https://www.bloomberg.com/n||qi||investorshub||06/07/2020 2:44:49 PM|
|Galapagos $GLPG & $GILD Shares Rise On||BottomBounce||investorshub||06/05/2020 5:09:37 PM|
News, Short Squeeze, Breakout and More Instantly...
Galapagos NV Company Name:
GLPG Stock Symbol:
Galapagos NV Website:
First nine months 2023 key financials: Group revenues of €448.9 million Jyseleca® net sales of €82.1 million Cash and current financi...
First nine months 2023 key financials: Group revenues of €448.9 million Jyseleca® net sales of €82.1 million Cash and current financial investments of €3.8 billion at 30 September 2023 Full year 2023 net Jyseleca® sales guidance of ...
Acushnet Holdings Corp. (GOLF) is expected to report $0.54 for Q3 2023 Paramount Global (PARA) is expected to report $0.09 for Q3 2023 Curis Inc. (CRIS) is expected to report $-2.32 for Q3 2023 Quanta Services Inc. (PWR) is expected to report $1.99 for Q3 2023 GRI Bio Inc. (GRI) i...